Renal Cell Carcinoma| Genitourinary Oncology

Casdatifan Plus Cabozantinib Shows Median PFS of 14.5 Months in Second-Line Clear Cell RCC

OncoNexus Staff October 21, 2026

Arcus Biosciences disclosed updated data from its ARC-20 study showing that casdatifan combined with cabozantinib produced a median progression-free survival of 14.5 months in patients with second-line clear cell renal cell carcinoma (ccRCC). The figures…

Kidney illustration with headline reporting 14.5-month median PFS with casdatifan plus cabozantinib in second-line clear cell RCC.

HR, Breast Cancer

FDA Clears MRI-Derived AI Tool to Assess Recurrence Risk in Early-Stage Breast Cancer

Non-Muscle Invasive (NMIBC), Bladder Cancer

FDA Accepts UGN-103 Application for Recurrent Low-Grade Intermediate-Risk NMIBC

Non-Muscle Invasive (NMIBC)

Anktiva Plus BCG Shows 84% Cystectomy Avoidance at Three Years in BCG-Unresponsive NMIBC

Oncology

FDA Advisory Committee Supports Approval of Galleri Multi-Cancer Early Detection Test

View All

View All

FDA Clears MRI-Derived AI Tool to Assess Recurrence Risk in Early-Stage Breast Cancer

October 20, 2026

SimBioSys announced on October 15, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance for TumorSight Risk,…

Tucatinib Plus Trastuzumab and Pertuzumab Approved for HER2-Positive Breast Cancer Maintenance Therapy

October 8, 2026

The United States (US) Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination…

Ataraxis AI Model Predicts Neoadjuvant Therapy Response From Breast Tumor Biopsies

October 7, 2026

Ataraxis AI has published details of a two-stage artificial intelligence framework designed to predict pathological complete response (pCR) to neoadjuvant…

[sureforms id=’2716′]

View All

AI & Cancer Insights, Breast Cancer

ASCO Deploys AI to Rethink Breast Cancer Trial Site Selection

ASCO and Ryght AI are using artificial intelligence to optimize clinical trial site selection for the CDK4/6 Inhibitor Dosing Knowledge…

Blood Cancer

ASH 2025: Advances in Individualized Leukemia Care: Insights from GIMEMA and AUGMENT-101 Trials

Explore recent pivotal trials in AML and CLL, highlighting MRD-guided therapy, targeted agents, and chemotherapy-sparing strategies. GIMEMA and AUGMENT-101 studies…

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

OncologyNexus Team August 13, 2025

SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but…

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer

OncologyNexus Team August 13, 2025

ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes…

Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort

OncologyNexus Team August 18, 2025

PTL is a rare extranodal malignancy accounting for <5% of thyroid cancer,…

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

August 5, 2025 No Comments

XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV…

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

August 6, 2025 No Comments

CR rates greater than 80% achieved with TAR-200 device -…

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

August 7, 2025 No Comments

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast…

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

August 13, 2025 No Comments

T-DXd plus pertuzumab nearly doubled progression-free survival compared to standard…

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

OncologyNexus Team August 12, 2025

“Steroids were the biggest predictor of why certain immunotherapies may not be…

Casdatifan Plus Cabozantinib Shows Median PFS of 14.5 Months in Second-Line Clear Cell RCC

FDA Clears MRI-Derived AI Tool to Assess Recurrence Risk in Early-Stage Breast Cancer

FDA Accepts UGN-103 Application for Recurrent Low-Grade Intermediate-Risk NMIBC

Anktiva Plus BCG Shows 84% Cystectomy Avoidance at Three Years in BCG-Unresponsive NMIBC

FDA Advisory Committee Supports Approval of Galleri Multi-Cancer Early Detection Test

FDA Clears MRI-Derived AI Tool to Assess Recurrence Risk in Early-Stage Breast Cancer

Tucatinib Plus Trastuzumab and Pertuzumab Approved for HER2-Positive Breast Cancer Maintenance Therapy

Ataraxis AI Model Predicts Neoadjuvant Therapy Response From Breast Tumor Biopsies

ASCO Deploys AI to Rethink Breast Cancer Trial Site Selection

ASH 2025: Advances in Individualized Leukemia Care: Insights from GIMEMA and AUGMENT-101 Trials

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer

Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

ASPEN-06: Evorpacept Combination Shows Higher Response Rates in HER2-Positive Gastric Cancer

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

ESMO Congress 2026

Latest Podcasts

Latest Videos

Latest Updates from OncoNexus

Latest Updates in Genitourinary Oncology

Latest Updates in Breast Cancer

Latest Updates in Lung Cancer

Latest Updates in GI Cancer

Latest Updates in Oncology